(Q54130015)

English

Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9684656

1 reference

Europe PubMed Central

Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9684656

author name string

M Dowzicky

1

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9684656

H L Nadler

2

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9684656

C Feger

3

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9684656

G Talbot

4

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9684656

F Bompart

5

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9684656

M Pease

6

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9684656

language of work or name

0 references

publication date

1 May 1998

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9684656

American Journal of Medicine

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9684656

104

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9684656

5A

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9684656

34S-42S

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9684656

Transferable vancomycin and teicoplanin resistance in Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

Emergence of vancomycin resistance in the genus Streptococcus: characterization of a vanB transferable determinant in Streptococcus bovis.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

Antibiotic resistance and serotypes of Streptococcus pneumoniae at Birmingham Public Health Laboratory, 1989-94.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

Prevalence of antibiotic resistance and serotypes in pneumococci in England and Wales: results of observational surveys in 1990 and 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995. The Italian Surveillance Group for Antimicrobial Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a university hospital in Korea.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

The molecular basis of the inhibitory activities of type A and type B synergimycins and related antibiotics on ribosomes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

RP 59500: a proposed mechanism for its bactericidal activity

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

The in-vitro activity of a new semi-synthetic streptogramin compound, RP 59500, against staphylococci and respiratory pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

In-vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

In-vitro antibacterial activity of RP 59500, a semisynthetic streptogramin, against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

Activity of quinupristin/dalfopristin against Streptococcus pneumoniae in vitro and in vivo in the rabbit model of experimental meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900153-3

7 January 2021

Identifiers

10.1016/S0002-9343(98)00153-3

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9684656

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9684656

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54130015&oldid=1975632855"